CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Patients with the treatment agains COVID19Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug1002 pirfenidone Wiki 1.00

Correlated MeSH Terms (3)

Name (Synonyms) Correlation
D011014 Pneumonia NIH 0.08
D045169 Severe Acute Respiratory Syndrome NIH 0.07
D018352 Coronavirus Infections NIH 0.06

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0002090 Pneumonia HPO 0.15

There is one clinical trial.

Clinical Trials

1 Observational Study of Follow-up of Hospitalized Patients Diagnosed With COVID-19 to Evaluate the Effectiveness of the Drug Treatment Used to Treat This Disease. COVID-19 Registry

The infection caused by COVID19 worldwide makes it necessary to monitor drugs administered for the treatment of patients hospitalized with SARS-CoV-2. In order to know more about the efficacy and safety of the treatments used, researchers from the Cantabrian health service have developed an observational study, in the form of an ambispective registry, in which clinical data from patients treated with the different drugs currently recommended by the Spanish Agency of Medicines and Health Products (SAMHP) and the Ministry of Health, or others that may arise, are collected and analyzed. Although the conduct of clinical trials is a priority at this time, we cannot lose the clinical experience that is currently being generated, which may allow us to improve the therapeutic strategies for future patients.

NCT04347278 SARS-CoV-2 Drug: Patients with the treatment agains COVID19

Primary Outcomes

Description: measured in terms of clinical stability

Measure: Effectiveness of current drug treatments for hospitalized patients with SARS-CoV-2 infection (COVID-19 patients) in routine clinical practice

Time: 6 months

Description: measured in terms of clinical recovery

Measure: Effectiveness of current drug treatments for hospitalized patients with SARS-CoV-2 infection (COVID-19 patients) in routine clinical practice

Time: 6 months

Description: measured in terms of clinical mortality.

Measure: Effectiveness of current drug treatments for hospitalized patients with SARS-CoV-2 infection (COVID-19 patients) in routine clinical practice

Time: 6 months

Secondary Outcomes

Measure: Risk factors or modifiers of pharmacological effect such as demographic characteristics, comorbidity or underlying pathology, concomitant medication.

Time: 6 months

Description: to know the use according to the Ministry of Health Technical Document

Measure: Information on the patterns of use of these drugs (dose, duration of treatment,

Time: 8 months

Description: Adverse effects of the medicines used

Measure: Adverse events

Time: 8 months

Measure: Time of hospital admission and/or stay in ICU and maximum severity reached.

Time: 8 months

Description: Determine the evolution of the treatments

Measure: Treatments for SARS-CoV-2 positive patients not described in the protocol

Time: 8 months

Description: It is composed of 10 items, with scores from 0 (worst health) to 100 points (best health)

Measure: healthy survey for patients after their recovery/discharge from hospital.

Time: 6 months

No related HPO nodes (Using clinical trials)